Antisense 2'-deoxy, 2'-fluoroarabino nucleic acid (2'F-ANA) oligonucleotides: In vitro gymnotic silencers of gene expression whose potency is enhanced by Fatty Acids

Molecular Therapy Nucleic Acids

Volumn 1, Issue 10, 2012, Pages e43-

  Souleimanian, Naira ^a   Deleavey, Glen F ^b   Soifer, Harris ^a   Wang, Sijian ^a   Tiemann, Katrin ^c   Damha, Masad J ^b   Stein, Cy A ^a,c  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

2'F ANA; endocytosis; Gymnosis; LNA; Oleic acid; Phosphorothioate oligonucleotides; Polyunsaturated fatty acids

Indexed keywords

EID: 84868342651     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.35     Document Type: Article

References (33)

1. Zelphati, O and Szoka, FC Jr (1996). Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm Res 13: 1367-1372. (Pubitemid 26344983)
2. Lungwitz, U, Breunig, M, Blunk, T and Göpferich, A (2005). Polyethylenimine-based nonviral gene delivery systems. Eur J Pharm Biopharm 60: 247-266. (Pubitemid 40804565)
3. Lv, H, Zhang, S, Wang, B, Cui, S and Yan, J (2006). Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 114: 100-109. (Pubitemid 44128621)
4. Xu, L and Anchordoquy, T (2011). Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci 100: 38-52.
5. Stein, CA, Hansen, B, Lai, J, Wu, S, Voskresenskiy, A, Hoeg, A et al. (2009) Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides unassisted by transfection reagents. Nucl Acids Res.
6. Zhang, Y, Qu, Z, Kim, S, Shi, V, Liao, B, Kraft, P et al. (2011). Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Gene Ther 18: 326-333.
7. Soifer, HS, Koch, T, Lai, J, Hansen, B, Hoeg, A, Oerum, H et al. (2012). Silencing of gene expression by gymnotic delivery of antisense oligonucleotides. Methods Mol Biol 815: 333-346.
8. Singh, S, Nielsen, P, Koshkin, A and Wengel, J (1998). LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition. Chem Commun 455-456. (Pubitemid 128675297)
9. Koch, T, Rosenbohm, C, Hansen, H, Hansen, B, Straarup, E and Kauppinen, S. (2008). Locked Nucleic Acid: Properties and Therapeutic Aspects. In Kurreck, J (ed), Therapeutic Oligonucleotides. RSC Publishing, Cambridge, pp. 103-134.
10. Damha, MJ, Wilds, CJ, Noronha, A, Brukner, I, Borkow, G and Parniak MA (1998). Hybrids of RNA and arabinonucleic acids (ANA and 2'F-ANA are substrates of ribonuclease H. J Amer Chem Soc 121:12976-12977. (Pubitemid 29013857)
11. Watts, J and Damha, MJ. (2008) 2'-Fluoroarabinonucleic acids (2'F-ANA): history, properties and new frontiers. Can J Chem 86:641-656.
12. Lok, CN, Viazovkina, E, Min, KL, Nagy, E, Wilds, CJ, Damha, MJ et al. (2002). Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2'-deoxy-2'-fluoro-d-arabinose and 2'-deoxyribose nucleotides. Biochemistry 41: 3457-3467. (Pubitemid 34214044)
13. Kalota, A, Karabon, L, Swider, CR, Viazovkina, E, Elzagheid, M, Damha, MJ et al. (2006). 2'-deoxy-2'-fluoro-beta-d-arabinonucleic acid (2'F-ANA) modified oligonucleotides (ON) effect highly efficient, and persistent, gene silencing. Nucleic Acids Res 34: 451-461. (Pubitemid 43240235)
14. Watts, JK, Katolik, A, Viladoms, J and Damha, MJ (2009). Studies on the hydrolytic stability of 2'-fluoroarabinonucleic acid (2'F-ANA). Org Biomol Chem 7: 1904-1910.
15. Wilds, CJ and Damha, MJ (2000). 2'-Deoxy-2'-fluoro-beta-d- arabinonucleosides and oligonucleotides (2'F-ANA): synthesis and physicochemical studies. Nucleic Acids Res 28: 3625-3635.
16. Scher, HI and Sawyers, CL (2005). Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23: 8253-8261. (Pubitemid 46211563)
17. Soifer, HS, Souleimanian, N, Wu, S, Voskresenskiy, AM, Collak, FK, Cinar, B et al. (2012). Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem 287: 3777-3787.
18. Eder, IE, Hoffmann, J, Rogatsch, H, Schäfer, G, Zopf, D, Bartsch, G et al. (2002). Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 9: 117-125. (Pubitemid 34141913)
19. Khaled, Z, Ho, YY, Benimetskaya, L, Deckelbaum, RJ and Stein, CA (1999). Omega-6 polyunsaturated fatty acid-stimulated cellular internalization of phosphorothioate oligodeoxynucleotides: evidence for protein kinase C-zeta dependency. Biochem Pharmacol 58: 411-423. (Pubitemid 29281540)
20. Laktionov, PP, Dazard, JE, Vives, E, Rykova, EY, Piette, J, Vlassov, VV et al. (1999). Characterisation of membrane oligonucleotide-binding proteins and oligonucleotide uptake in keratinocytes. Nucleic Acids Res 27: 2315-2324. (Pubitemid 29245650)
21. Yakubov, LA, Deeva, EA, Zarytova, VF, Ivanova, EM, Ryte, AS, Yurchenko, LV et al. (1989). Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc Natl Acad Sci USA 86: 6454-6458. (Pubitemid 19236298)
22. Lebedeva, I, Benimetskaya, L, Stein, CA and Vilenchik, M (2000). Cellular delivery of antisense oligonucleotides. Eur J Pharm Biopharm 50: 101-119. (Pubitemid 30326691)
23. Wallace, T, Cossum, P and Cameron, P. (1998). Pharmacokinetics of oligonucleotides: A review of current knowledge and issues for the future. In Stein, C and Krieg, A. (eds.) Applied Antisense Oligonucleotide Technology. Wiley-Liss, NY, pp. 407-429.
24. Pouysségur, J, Dayan, F and Mazure, NM (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443. (Pubitemid 44050138)
25. Jain, RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62. (Pubitemid 40093472)
26. Jain, RK (1999). Understanding barriers to drug delivery: high resolution in vivo imaging is key. Clin Cancer Res 5: 1605-1606. (Pubitemid 29334434)
27. Felber, AE, Bayó-Puxan, N, Deleavey, GF, Castagner, B, Damha, MJ and Leroux, JC (2012). The interactions of amphiphilic antisense oligonucleotides with serum proteins and their effects on in vitro silencing activity. Biomaterials 33: 5955-5965.
28. Kim, JH, Kim, Y, Lee, SD, Lopez, I, Arnold, RS, Lambeth, JD et al. (1999). Selective activation of phospholipase D2 by unsaturated fatty acid. FEBS Lett 454: 42-46. (Pubitemid 29296922)
29. Mettlen, M, Platek, A, Van Der Smissen, P, Carpentier, S, Amyere, M, Lanzetti, L et al. (2006). Src triggers circular ruffling and macropinocytosis at the apical surface of polarized MDCK cells. Traffic 7: 589-603. (Pubitemid 44026756)
30. Morris, AJ (2007). Regulation of phospholipase D activity, membrane targeting and intracellular trafficking by phosphoinositides. Biochem Soc Symp : 247-257.
31. Chalifa, V, Möhn, H and Liscovitch, M (1990). A neutral phospholipase D activity from rat brain synaptic plasma membranes. Identification and partial characterization. J Biol Chem 265: 17512-17519.
32. Parmentier, JH, Smelcer, P, Pavicevic, Z, Basic, E, Idrizovic, A, Estes, A et al. (2003). PKC-zeta mediates norepinephrine-induced phospholipase D activation and cell proliferation in VSMC. Hypertension 41(3 Pt 2): 794-800. (Pubitemid 36314593)
33. Nakamura, S, Shimooku, K, Akisue, T, Jinnai, H, Hitomi, T, Kiyohara, Y et al. (1995). Mammalian phospholipase D: activation by ammonium sulfate and nucleotides. Proc Natl Acad Sci USA 92: 12319-12322. (Pubitemid 26014062)